共 50 条
- [1] Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancerMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Yao, ShugangCui, YunKazanats, AnnaGong, LiyingBonfils, ClaireHou, DominicChen, EmilyUndzys, ElijusToulouse, JacyntheKrstic, MilicaZahreddine, HibaMatos, IsraelZhou, AlexMoya-Torres, AnielWargachuk, RichardGay, CarlByers, LaurenNgan, Gordonda Cruz, LuisYoung, David
- [2] OVERCOMING IMMUNE EVASION IN PEDIATRIC BRAIN TUMORS: A PRE-CLINICAL DEVELOPMENT STUDY USING A HUMANIZED ANTI-CD47 ANTIBODYNEURO-ONCOLOGY, 2014, 16 : 138 - 138Gholamin, ShararehMitra, SiddharthaFeroze, AbdullahZhang, MichaelEsparza, RogelioKahn, SuzannaRichard, ChaseAchrol, AchalVolkmer, AnneLiu, JieVolkmer, JensMajeti, RaviWeissman, IrvingCheshier, Samuel
- [3] IOH-001, a novel CD47/PD-L1 bispecific antibody, enhances anti-tumor activity in solid tumorsCANCER RESEARCH, 2022, 82 (12)Kim, Jeong-kookJeon, A-RaPark, JihyunChoi, Ji YeaPark, Ji EunSong, Sun KwangChoi, Ji HyeShin, HeewookLee, Ji HyeYun, Ji HyeAhn, Yoen HeeKim, Heung Tae
- [4] Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic PotentialPLOS ONE, 2015, 10 (09):Liu, JieWang, LijuanZhao, FeifeiTseng, SerenaNarayanan, CyndhaviShura, LeiWillingham, StephenHoward, MaureenProhaska, SusanVolkmer, JensChao, MarkWeissman, Irving L.Majeti, Ravindra
- [5] Discovery and pre-clinical development of an orally available small molecule antagonist targeting the CD47/SIRPa pathway for cancer immunotherapyJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Sasikumar, PottayilGundala, ChennakrishnaBalasubramanian, WesleyNaremaddepalli, SudarshanBhumireddy, ArchanaPatil, SandeepDhudashiya, AmitRayavarapu, VijaysaiLakshminarasimhan, AnirudhaDodheri, SamiullaAithal, KiranDaginakatte, GirishRamachandra, Murali
- [6] An IND-ready anti-CD4 monoclonal antibody in combination with PD-1 inhibitors for the treatment of solid tumorsEUROPEAN JOURNAL OF CANCER, 2024, 211 : S166 - S167Nakano, Y.Price, L.Dubey, S. K.Duthoit, I.Cayatte, P. A.Kim, H.
- [7] CD47 ANTIBODY, AO-176 DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL SOLID TUMOR XENOGRAFTS AS A SINGLE AGENT AND IN COMBINATION WITH MULTIPLE CLASSES OF THERAPEUTICSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A282 - A282Andrejeva, GabrielaCapoccia, BenjaminDelston, RachelDonio, MichaelHiebsch, RonaldPuro, RobynWilson, CaseyKashyap, ArunPereira, Daniel
- [8] NI-2601, an Fc-active CD47xPD-L1 bispecific antibody that selectively targets CD47 on PD-L1positive tumorsCANCER RESEARCH, 2022, 82 (12)Chauchet, XavierBosson, NicolasLegrand, MargauxCons, LauraCalloud, SebastienViandier, AlizeeRichard, FrancoiseMalinge, PaulineBautzova, TerezaBourguignon, JeremiePontini, GuillemettePenarrieta, EliseSun, MengzhuRavn, UllaMoine, ValeryMagistrelli, GiovanniPoitevin, YvesHugues, StephanieShang, LiminFerlin, WalterMasternak, Krzysztof
- [9] Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumorsIMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1584 - 1595Wang, MiaoZhen, HongchaoJiang, XiaoyueLu, YutingWei, YuhanJin, JiangtaoLi, Qin
- [10] Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatmentTHERANOSTICS, 2023, 13 (01): : 148 - 160Wang, RongjuanZhang, ChangCao, YutingWang, JunchaoJiao, ShashaZhang, JiaoWang, MinTang, PeipeiOuyang, ZijunLiang, WenluMao, YuWang, AnLi, GangZhang, JinchaoWang, MingzhuWang, ShuangGui, Xun